CureLab Oncology, a clinical-stage biotech company, announced on Thursday that it has named Dr Aubrey C Galloway as its new chief medical officer (CMO).

In the new role, Dr Galloway will manage the clinical development strategy for the company's lead investigational compound, Elenagen, and new forms of treatment that CureLab is presently developing.

Dr Galloway is a cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health. He has directed the department's Cardiac Surgery Research and Clinical Trials program for more than 20 years and worked as Chair of the Department of Cardiothoracic Surgery for 15 years.